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Objective: Neoadjuvant chemotherapy (NAC) followed by radical surgery is the 
standard treatment for patients with resectable esophageal squamous cell carcinoma 
(ESCC) in Japan. However, some adverse events associated with NAC may result in a 
decrease in physical fitness that may influence the patient’s ability to tolerate surgery. 
The purpose of this study was to evaluate the impact of NAC on the physical fitness, 
physical activity and health-related quality of life (HRQOL) of patients with ESCC.  
Methods: In this prospective study, we investigated 27 consecutive patients with newly 
diagnosed resectable ESCC who were scheduled to receive NAC followed by surgery 
between January 2009 and November 2010. Primary endpoints were change from 
baseline in physical fitness (knee-extensor muscle strength and six-minute walking 
distance) and physical activity after NAC. A secondary endpoint was change from 
baseline in HRQOL.  
Results: Physical fitness and physical activity level after NAC did not differ 
significantly from those before NAC. With regard to HRQOL, only social functioning 
was significantly different (P = 0.04). The change in physical activity demonstrated a 




Conclusions: NAC had no impact on physical fitness and physical activity in patients 
with ESCC. This result indicated that there was no need for a physiotherapy 
intervention during NAC to prevent a decline in these parameters. 
 





Esophageal cancer was the eighth most common malignancy (482,000 cases, 3.8% of 
all cancers) and the sixth leading cause of cancer death (406,000 deaths, 5.4% of all 
cancers) worldwide in 2008.
1
 Despite optimal treatment, median survival for advanced 
disease remains less than 1 year. Even in patients with resectable disease, the prognosis 
is relatively poor after surgery alone.
2-4
 This fact has prompted many investigators to 
explore perioperative systemic treatment, such as chemotherapy or chemoradiotherapy, 
to improve survival. In Japan, on the basis of the results of several studies, such as 
JCOG 9204 and JCOG 9907, neoadjuvant chemotherapy (NAC) with cisplatin 
combined with 5-fluorouracil (5-FU) followed by radical surgery has become the 




Although NAC is a well-established treatment for improving the outcomes of surgery, 
several side effects may result in the deterioration of physical fitness, physical activity, 
and health-related quality of life (HRQOL). Recently, several studies reported the 
impact of neoadjuvant treatment (chemotherapy or chemoradiotherapy) on HRQOL.
7-9
 
However, there are no reports on the impact of NAC on physical fitness or physical 
activity. It is important to clarify whether these parameters will be decreased by NAC, 
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because the compromise of physical fitness by NAC may negatively influence the 
tolerability and outcome of surgery. In addition, the results of this study will be useful to 
determine whether a physiotherapy intervention is necessary during the neoadjuvant 
treatment period to improve these parameters. 
The objectives of this study were to evaluate the impact of NAC on physical fitness, 
physical activity and HRQOL in patients with ESCC and to determine whether 
physiotherapy is needed during the NAC period.  
 
<Materials and Methods> 
Study Design and Subjects 
This was a single-center, prospective study conducted to evaluate the impact of NAC 
on the physical fitness, physical activity and HRQOL of patients with resectable ESCC. 
The Institutional Review Board of Kyoto University Graduate School of Medicine 
approved the protocol and consent form for this study, and written informed consent 
was obtained from all patients. Between January 2009 and November 2010, patients 
with newly diagnosed ESCC who were scheduled to receive NAC followed by surgery 
were asked to participate in this study. All patients who were scheduled to receive NAC 
followed by surgery were eligible. Patients with gait disturbances or cognitive 
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impairment were excluded. Preoperative chemotherapy consisted of two cycles of 
cisplatin (80 mg/m
2
, intravenously) on day 1 and 5-FU (800 mg/m
2
 per day in a 
continuous infusion) on days 1 through 5 at 3-week intervals. Primary outcomes were 
physical fitness (knee-extensor muscle strength and six-minute walking distance) and 
physical activity. The secondary outcome was HRQOL. We assessed these outcomes 
before the initiation of NAC (pre-NAC) and after the completion of NAC (post-NAC).  
Demographic and Treatment Information 
 Information regarding age, gender, weight, clinical stage, histologic tumor type, and 
side effects was obtained from electronic medical records. Side effects were assessed 
with the National Cancer Institute Common Terminology Criteria for Adverse Events 
v3.0 (NCI-CTCAE v3.0). The NCI-CTCAE measure toxicities as grades 1 through 5 (1 
is mild, 2 is moderate, 3 is severe, 4 is life-threatening or disabling, and 5 is death 
associated with the adverse event).  
 
Physical Fitness 
 To assess physical fitness, we tested knee-extensor muscle strength and 6-minute 
walking distance. Knee-extensor muscle strength was assessed with an isometric 
knee-extensor muscle strength machine (IsoForce GT-330, OG GIKEN, Japan). The 
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subject was in the sitting position, and the hip and knee were kept at 90° angles. The 
maximal isometric strength was measured after adequate premeasurement trials. The 
6-minute walking distance was measured with the 6-minute Walk Test, as described by 
the American Thoracic Society.
10
 Subjects walked as far and as fast as they could for 6 
minutes. (Subjects were allowed to rest if and as necessary during the 6-minute period.) 
These tests were conducted by physiotherapists who had been trained in the proper 
techniques for conducting them.  
Physical Activity 
 Physical activity status was assessed using the last 7-days short version of the 
International Physical Activity Questionnaire (IPAQ) Japanese version.
11, 12
 This 
measure assessed total vigorous intensity physical activity, total moderate intensity 
physical activity, total time walking, and time spent sitting during the last 7 days. Each 
activity type and intensity score is provided a Metabolic equivalent (MET) value 
according to the published protocol (e.g., MET for walking = 3.3, cycling = 6.0, 
moderate intensity = 4.0, vigorous intensity leisure = 8.0) (Craig, IPAQ. At a glance: 
IPAQ Scoring Protocol. http://www.ipaq.ki.se/scoring.htm. Accessed March 20, 2006). 




Health-Related Quality of Life 
HRQOL was measured with the European Organization for the Research and 
Treatment of Cancer Quality of Life Core Questionnaire with 30 items (EORTC 
QLQ-C30).
13
 This QOL scale includes a global health status/QOL scale, five functional 
scales (physical, role, emotional, cognitive, and social functioning), and symptom scales 
(fatigue, nausea-vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, 
and financial problems). Calculation of scores was carried out according to the EORTC 




Sample Size Calculation and Statistical Analysis 
 Sample size calculation was based on the difference in the 6-minute Walk Test; 
primary outcome in this study. Since the walking distance of 54 meters (standard 
deviation = 93) was thought to be clinically important difference
15-18
, the estimated 
sample sizes required to achieve a power of the test of 80% and a two-sided level of 
significance of 5% were calculated as 27 patients.  
Demographic and treatment variables were described using means and standard 
deviations, medians and ranges and percentages, where appropriate. All variables were 
tested for distribution normality using the Shapiro-Wilks normality test. Differences 
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over the course of NAC (pre to post-treatment) were analyzed using paired-sample t-test 
for continuous variables with normal distribution (weight, knee-extensor muscle 
strength, and 6-minute walking distance) and the Wilcoxon signed-rank test for 
non-normally distributed variables (IPAQ score and HRQOL scores). Spearman’s rank 
correlation coefficient was used to evaluate the relationship between changes in 
physical activity and changes in physical fitness. All statistical analyses were performed 
with the R statistical package (www.r-project.org). All hypothesis testing was two-tailed, 
and P values of less than 0.05 were considered to indicate statistical significance. 
 
<Results> 
 During the study period, 33 patients with ESCC underwent NAC before surgery. 
Among them, 6 were excluded because of gait disturbances (n = 2), cognitive 
impairment (n = 1), and declined participation (n = 3), so the remaining 27 patients were 
properly registered and underwent NAC. Patient demographic and treatment data are 
presented in Table 1. The mean age was 63 years, and 81% were men. The baseline 
clinical stage (UICC-TNM stage 6
th
 edition) at enrollment was IIA in 11 (41%) patients, 
IIB in 10 (37%) patients, III in 5 (18%) patients, and IVA in 1 (4%) patient. The 
histologic type was squamous cell carcinoma in all patients. The occurrence of side 
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effects was as follows: Grade 1 in 23 (85%) patients, Grade 2 in 16 (59%) patients, 
Grade 3 in 3 (11%) patients, and Grade 4 in 1 (4%) patient. The Grade 3 
chemotherapy-related toxicities were mucositis, abdominal pain, and thrombocytopenia. 
The Grade 4 chemotherapy-related toxicity was hyponatremia. Most patients underwent 
two cycles of preoperative chemotherapy, although 5 (19%) patients underwent only 
one cycle because of severe adverse events (n = 2) and progression of disease (n = 3).  
 Table 2 shows changes in weight, physical fitness data, and physical activity over the 
course of NAC. Post-NAC variables did not differ significantly from pre-NAC variables. 
With regard to the global health status/QOL scale, functional scales, and symptom 
scales, there was a statistically significant difference only in terms of social functioning 
(P = 0.04; Table 3).  
 Results of the correlational analysis are presented in Figure 1A and 1B. The change in 
physical activity demonstrated a significant correlation with the change in 6-minute 
walking distance (r = 0.45, P = 0.02), but not with the change in knee-extensor muscle 
strength (r = -0.01, P = 0.95).  
 
<Discussion> 
 This is the first report regarding the impact of NAC on physical fitness and physical 
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activity. Results of this prospective study suggested that NAC had no impact on 
physical fitness, physical activity, and HRQOL in patients with ESCC. We hypothesized 
that physical activity would decrease because of adverse events, leading to a 
deterioration in physical fitness. Several studies have reported that treatment (surgery 
and/or chemotherapy and/or radiation) had a significant negative effect on physical 
activity.
19, 20
 In our study, however, physical fitness and physical activity levels did not 
decrease over the course of NAC. In addition, the change in physical activity 
demonstrated a significant positive correlation with the change in 6-minute walking 
distance. These results indicated that patients who maintained their pretreatment 
physical activity levels could maintain physical fitness, especially the 6-minute walking 
distance. Although most patients in this study experienced some kind of adverse event, 
the severity of these adverse events was relatively mild. This seemed to be one of the 
reasons that most patients could maintain their physical activity levels. Similarly, 
HRQOL scores did not deteriorate significantly over the course of NAC, except for 
social functioning. Our findings are similar to previous work by Safieddine and 
colleagues, who reported that the impact of NAC on HRQOL in patients with operable 






 It was important to understand the impact of NAC on physical fitness, physical activity, 
and HRQOL in patients with ESCC to determine the need for a physiotherapy 
intervention to improve these parameters during NAC. The results of the present study 
indicated that there was no need for a physiotherapy intervention during NAC. However, 
Nagamatsu and colleagues reported that esophagectomy can be safely performed in 










 Thus, physiotherapy may be 
important before surgery to reduce the risk of postoperative cardiopulmonary 
complications. Further studies are needed to examine the role of physiotherapy in the 
treatment of ESCC comprehensively. 
 This study has some limitations. First, our study was conducted with small sample size, 
which might not have had enough power to detect significant differences in outcomes. It 
was possible that each outcome might reach statistical significance with more patients. 
However, even so, they might not be clinically significant; such as 1 kg weight loss, 
minimal difference in knee strength, or 2% difference in walk distance. Although only 
the 17% difference in IPAQ might be clinically significant difference with more patients, 
the conclusion of this study might not be changed, because IPAQ was the secondary 
outcome. In addition, the small sample size precluded subgroup analyses stratified by 
the demographic and treatment characteristics of the patients. Second, we evaluated the 
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impact of chemotherapy alone as a neoadjuvant treatment, because NAC followed by 
surgery is the standard treatment for the patients with resectable disease in Japan. 
However, the standard neoadjuvant treatment for the esophageal cancer in Western 
countries; such as in US or in Europe, is chemotherapy with more strong combination 
regimen or chemoradiotherapy. Although it might be possible that inclusion of patients 
who received neoadjuvant chemoradiotherapy or different regimen of NAC might have 
changed the results of this study, we could not discuss about it from the results of this 
study. Third, the frequency of the excluded patients (6 patients [18.2%]) was relatively 
high in this study with the small sample size. Moreover, among them, 2 patients were 
excluded because of gait disturbances. This might introduce a potential of selection bias, 
because the finally analyzed patients were limited to the patients with relatively better 
condition. The fourth limitation was the assessment of physical activity. The Japanese 
short version of IPAQ is validated and reliable. However, it is not a direct assessment 
tool of real physical activity, such as daily walking steps.
22, 23
 Thus, it should be noted 
that the IPAQ data alone were probably insufficient to draw definitive conclusions that 
patients maintained their physical activity levels during NAC.   
 In conclusion, NAC had no impact on physical fitness, physical activity, and HRQOL 
in patients with ESCC. The results of this study indicated that there was no need to 
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implement a physiotherapy intervention during NAC to prevent a decline in these 
parameters. Since the number of patients was rather small, and the assessment tool used 
was insufficient, further study of a larger number of cases with more quantitative 
assessment tools is required to confirm the impact of NAC on physical fitness, physical 
activity, and HRQOL.  
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Fig 1. Relationship between changes in physical activity and changes in physical fitness. The 
change in 6-minute walking distance was correlated positively with the change in IPAQ (r = 0.45, 
P = 0.02; A), whereas the change in knee-extensor muscle strength had no correlation (r = -0.01, 















Table 1. Characteristics of subjects N = 27 (%)
Age (Mean ± SD) 63.4±6.8
Gender
  Male 22 (81%)
  Female 5 (19%)
Clinical stage
  ⅡA 11 (48%)
  ⅡB 10 (37%)
  Ⅲ 5 (18%)
  ⅣA 1 (4%)
Histologic tumor type
  Adenocarcinoma 0 (0%)
  Squamous cell carcinoma 27 (100%)
Side effects
  Grade 1 23 (85%)
  Grade 2 16 (59%)
  Grade 3 3 (11%)
  Grade 4 1 (4%)
  Grade 5 0 (0%)
pre-NAC post-NAC p value
Weight (kg) 57.5±11.8 56.5±11.6 NS
Physical fitness
Knee-extensor muscles strength (N･m/kg) 2.5 ± 0.6 2.4 ± 0.5 NS
6-minute walk distance (m) 574.9 ± 77.8 565.1 ± 75.3 NS
Physical activity
IPAQ (METs･mins/day) 119.1 (0.0-605.6) 99.0 (0.0-819.0) NS
Table 2. Changes in weight, physical fitness data and physical activity over the course of NAC treatment
NS, not significant.
IPAQ values expressed as Median (range)





















pre-NAC post-NAC p value
global health status (QOL score) 66.7 (16.7-100.0) 66.7 (16.7-91.7) NS
Functional scales
  Physical 93.3 (66.7-100) 93.3 (60.0-100) NS
  Role 100 (33.3-100) 100 (33.3-100) NS
  Emotional 75.0 (41.7-100) 83.3 (50.0-100) NS
  Cognitive 83.3 (50.0-100) 83.3 (33.3-100) NS
  Social 100 (33.3-100) 83.3 (0-100) 0.04
Symptom Scales
  Fatigue 22.2 (0-55.6) 22.2 (0-66.7) NS
  Nausea and vomiting 0 (0-33.3) 0 (0-66.7) NS
  Pain 0 (0-50) 0 (0-33.3) NS
  Dyspnoea 0 (0-66.7) 0 (0-33.3) NS
  Insomnia 0 (0-66.7) 0 (0-66.7) NS
  Appetite loss 0 (0-66.7) 0 (0-100) NS
  Constipation 0 (0-100) 0 (0-100) NS
  Diarrhoea 0 (0-33.3) 0 (0-33.3) NS
  Financial difficulties 0 (0-100) 0 (0-100) NS
Values expressed as Median (range)
Table 3. Changes in EORTC QLQ-C30 over the course of NAC treatment
Scores range from 0 to 100 (higher score is higher level of functioning, higher score is greater degree of symptoms). 
NS, not significant.
